🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  2. Alpelisib

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  3. Alteplase

    United Therapeutics Europe Ltd

    Myocardial Infarction

    phase 2 small molecule completed

    1 trial

  4. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  5. Ametinib combined with bevacizumab

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Amikacin (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  7. Amikacin inhalation solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  8. Amiloride

    United Therapeutics Europe Ltd

    Secondary Progressive Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  9. Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  10. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  11. Amondys 45

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  12. An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Lacuna Pharma Pty Ltd

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  13. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  14. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  15. An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

    Swedish Orphan Biovitrum AB (publ)

    Transplant-associated Thrombotic Microangiopathy (TA TMA)

    phase 2 other active

    1 trial

  16. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  17. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  18. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  19. Angiotensin (1-7)

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  20. Anlotinib

    The First People's Hospital of Lianyungang

    Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. Anlotinib Hydrochloride

    The First People's Hospital of Lianyungang

    Effect of Drugs

    phase 2 small molecule active

    1 trial

  22. Anlotinib and Sintilimab injection

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  23. Anlotinib+ Liposomal Doxorubicin

    The First People's Hospital of Lianyungang

    Sarcoma

    phase 2 small molecule active

    1 trial

  24. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources